Table 1 Clinicopathological features of EIMSs described in present and previous reports
No. | Authors (yr.) | Age (year)/gender | Location/size (cm) | Clinical presentation | Immuno-phenotype | Molecular change | Recurrence | Metastasis | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Marino-Enriquez A (2011) [2] | 59/Male | Mesentery/15.0 | Abdominal pain and/or ascites | Des+, SMA+, ALK+(N) | ALK-rearrangement (FISH) | Yes | None | SE + CT | DOD 12 months after SE |
2 |  | 41/Male | Omentum/26.0 | Des+,CD30+, ALK+(N) | ALK-rearrangement (FISH)/RANBP2 -ALK fusion (PCR) | Yes | Liver | SE + CT + ALKi | ANED 40 months after SE | |
3 |  | 6/Male | Omentum/10.5 | Des+, SMA-, ALK+(N) | ALK-rearrangement (FISH) | Yes | None | SE + CT | AWD 13 months after SE | |
4 | Â | 28/Male | Mesentery/NA | Des+, SMA+, ALK+(N) | NA | NA | NA | NA | NA | |
5 |  | 63/Male | Mesentery/25.0 | Des+,CD30+, ALK+(P) | ALK-rearrangement (FISH) | Yes | None | SE + CT | DOD 3 months after SE | |
6 |  | 42/Male | Intra-abdominal/NA | Des+, ALK+(N) | NA | Yes | None | SE + CT | AWD 13 months after SE | |
7 |  | 7 mo/Male | Peritoneum/10.0 | Des+,CD30+, ALK+(N) | ALK-rearrangement (FISH) | Yes | None | SE + CT + RT | DOD 36 months after SE | |
8 |  | 40/Male | Peritoneum/8.0 | Des-, CD30+, ALK+(N) | ALK-rearrangement (FISH) | Yes | Lung, liver, lymph node | SE + CT + RT | DOD 28 months after SE | |
9 |  | 31/Female | Mesentery/17.5 | Des+,CD30+, ALK+(N) | ALK-rearrangement (FISH) | Yes | None | SE + CT | DOD 11 months after SE | |
10 | Â | 6/Male | Omentum and mesentery/14.0 | Des+,CD30+, ALK+(N) | ALK-rearrangement (FISH)/RANBP2 -ALK fusion (PCR) | NA | NA | SE | NA | |
11 | Â | 39/Male | Mesentery/15.0 | Des+,CD30+, ALK+(N) | ALK-rearrangement (FISH)/RANBP2 -ALK fusion (PCR) | NA | NA | SE | NA | |
12 | Kozu Y (2014) [3] | 57/Male | Pleural cavity / NA | Dyspnea and pleural effusion | Vim+, Des+, CK+, CD30-, ALK+ (C) | RANBP2-ALK fusion (PCR) | NA | NA | Biopsy + ALKi | NA |
13 | Kimbara S (2014) [4] | 22/Male | Pelvis/6.0 | Fever, fatigue, abdominal pain | Des+, SMA+, ALK+ (N) | RANBP2-ALK fusion (PCR) | Yes | Peritoneal dissemination | SE + Crizotinib | ANED 10 months after Crizotinib |
14 | Present case | 21/Male | Lung/10.0 | Fatigue and weight loss | Des+, CD30-, ALK+ (C) | ALK-rearrangement (FISH) | No | Multiple bone metastases | SE + Crizotinib | DOD 4 months after initial SE |